Abstracts tagged "Clinical research"

Abstract Number: 690 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
Philip J. Mease¹, Désirée van der Heijde², Robert B.M. Landewé³, Shephard Mpofu⁴, Proton Rahman⁵, Hasan Tahir⁶, Atul Singhal⁷, Elke Böttcher⁸, Sandra V. Navarra⁹, Xuan Zhu¹⁰, Aimee Readie¹⁰, Luminita Pricop¹¹ and Ken Abrams¹⁰, ¹Swedish Medical Centre and University of Washington, Seattle, WA, ²Leiden University Medical Centre, Leiden, Netherlands, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Memorial University of Newfoundland and Labrador, St. John's, NF, Canada, ⁶Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, ⁷Southwest Rheumatology, Dallas, TX, ⁸Rheumazentrum Favoriten, Vienna, Austria, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab (SEC), a fully human anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms and inhibited radiographic progression versus placebo (PBO) at Week (Wk) 24…
Abstract Number: 817 • 2018 ACR/ARHP Annual Meeting
Current Diagnostic Delays in Vasculitis and Factors Associated with Time to Diagnosis
Antoine G. Sreih¹, Dianne Shaw², Kalen Young³, Cristina Burroughs⁴, Joyce Kullman⁵, Kirthi Machireddy⁶, Carol A. McAlear¹, George Casey³ and Peter A. Merkel⁷, ¹Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ²University of North Carolina, Chapel Hill, NC, ³Vasculitis Foundation, Kansas city, MO, ⁴University of South Florida, Tampa, FL, ⁵Vasculitis, Vasculitis Foundation, Kansas City, MO, ⁶University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Despite recent advancements in the evaluation and management of vasculitis, patients with vasculitis continue to encounter diagnostic delays. These delays are often associated…
Abstract Number: 1400 • 2018 ACR/ARHP Annual Meeting
Effects of Childhood-Onset SLE on Academic Achievements and Employment in Adult Life
Noortje Groot¹, Marc Bijl², Radboud J. E. M. Dolhain³, Els J. Zirkzee⁴, Ruth D.E. Fritsch-Stork⁵, Y.K. Onno Teng⁶, Karina de Leeuw⁷, Irene E.M. Bultink⁸ and Sylvia S.M. Kamphuis⁹, ¹Paediatric Rheumatology, Erasmus Medical Centre - Sophia Children's Hospital, Rotterdam, Netherlands, ²Internal Medicine and Rheumatology, Martini Hospital, Groningen, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁹Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: To investigate the effects of cSLE on education, vocation and employment in a large cohort of adults with cSLE. Methods: Patients were seen by…
Abstract Number: 1410 • 2018 ACR/ARHP Annual Meeting
Assessment of Work Outcomes with Truncation from Job Loss in an Arthritis Randomized Clinical Trial
Michael P. LaValley¹, Carrie Brown^1,2, David T. Felson^3,4 and Julie Keysor⁵, ¹Biostatistics, Boston University School of Public Health, Boston, MA, ²The Emmes Corporation, Rockville, MD, ³ARC Epidemiology Unit, University of Manchester, Manchester, MA, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Physical Therapy, MGH Institute of Health Professions, Boston, MA
Background/Purpose: Methods for causal analysis in randomized clinical trials (RCT) where functional outcomes may be truncated by death of participants have been developed but are…
Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting
Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
Christof Specker¹, Annette Alberding², Martin Aringer³, Gerd R. Burmester⁴, Jan-Paul Flacke⁵, Michael Hofmann⁶, Peter Kaestner⁷, Herbert Kellner⁸, Frank Moosig⁹, Maren Sieburg¹⁰, Hans-Peter Tony¹¹ and Gerhard Fliedner¹², ¹Rheumatology and Clinical Immunology, Universitätsklinikum Essen, Essen, Germany, ²Internal Rheumatology, Krankenhaus St. Josef, Wuppertal, Germany, ³Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁶Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ⁷Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ⁸Ambulantes Rheumazentrum, Erfurt, Germany, ⁹Rheumatology Center Schleswig-Holstein Mitte, Neumuenster, Germany, ¹⁰Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, ¹¹Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany, ¹²Rheumatological Practice, Osnabrueck, Germany
Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…
Abstract Number: 1689 • 2018 ACR/ARHP Annual Meeting
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus
Nathaniel J. Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Department of Medicine, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus Background/Purpose: Patient-reported measures of disease activity provide useful adjuncts to…
Abstract Number: 1746 • 2018 ACR/ARHP Annual Meeting
Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis
Hiromi Matsushita¹, Yoshioki Yamasaki², Yukiko Takakuwa³, Hidehiro Yamada⁴ and Kimito Kawahata³, ¹Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan
Background/Purpose: ANCA-associated vasculitis including microscopic polyangiitis (MPA) involves multiple organs including lungs. Clinical characteristics and impact on long-term survival in MPA patients with interstitial lung disease (ILD) have not…
Abstract Number: 1855 • 2018 ACR/ARHP Annual Meeting
Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus
Jill P. Buyon¹, Peter M. Izmirly², H. Michael Belmont³, John Conklin⁴, Nicole Kaiden⁵, Jane E. Salmon⁶, Roberta Alexander⁴ and Thierry Dervieux⁴, ¹Medicine, New York University School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³Medicine, NYU Langone Health, New York, NY, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵Medicine, NYU School of Medicine, New York, NY, ⁶Medicine/Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Activation of the alternative and terminal attack complex of the complement system has been associated with adverse pregnancy outcomes (APOs) in stable/quiescent systemic lupus…
Abstract Number: 2292 • 2018 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Immunosuppressive Therapy for Polymyositis/Dermatomyositis
Yumiko Sugiyama¹, Ryusuke Yoshimi², Maasa Tamura², Mitsuhiro Takeno³, Yohei Kirino², Shigeru Ohno⁴ and Hideaki Nakajima², ¹Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM), intensive immunosuppressive treatment are necessary for severe cases.…
Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Nicola Ruperto¹, Hermine I. Brunner², Gabriel Vega-Cornejo³, Alberto Berman⁴, Rubén J. Cuttica⁵, Francisco Ávila-Zapata⁶, Michael Henrickson⁷, Daniel J Kingsbury⁸, John F. Bohnsack⁹, Thomas Lutz¹⁰, Nadina E Rubio-Pérez¹¹, Valeria Gerloni¹², Xiaohui Li¹³, Marleen Nys¹⁴, Robert Wong¹³, Alberto Martini¹⁵ and Daniel J Lovell¹⁶, ¹Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁵Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁶Star Medica Hospital, Merida, Yucatán, Mexico, ⁷Cincinnati Children’s Medical Center, Cincinnati, OH, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹University of Utah School of Medicine, Salt Lake City, UT, ¹⁰Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, ¹¹Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, ¹²Istituto Gaetano Pini, Milan, Italy, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…
Abstract Number: 2508 • 2018 ACR/ARHP Annual Meeting
A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis
David Chernoff¹, Yaakov Levine¹, Charles Peterfy² and Mark C. Genovese³, ¹SetPoint Medical, Inc., Valencia, CA, ²Spire Sciences LLC, Boca Raton, FL, ³Department of Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Rheumatoid arthritis (RA) is a debilitating chronic disease with an unmet need for additional therapeutic approaches. Bioelectronic therapy (BET), such as electrical neurostimulation of…
Abstract Number: 2630 • 2018 ACR/ARHP Annual Meeting
Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
Michelle Petri¹, John Conklin², Robert Apilado², Tyler O'Malley², JoAnne Ligayon², Leilani Wolover² and Thierry Dervieux², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Lupus anticoagulant (LAC) is an established risk factor for thrombosis in systemic Lupus erythematosus (SLE). Emerging data suggest that activation of the complement system…
Abstract Number: 2873 • 2018 ACR/ARHP Annual Meeting
Remaining Pain and Widespread, Non-Inflammatory Pain Distribution during the First 12 Months after RA Diagnosis
Yvonne C. Lee¹, Orit Schieir², Marie-France Valois³, Susan J. Bartlett⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol A Hitchon⁷, Edward C. Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Janet E. Pope¹¹ and Vivian P. Bykerk¹², ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²McGill University, Montreal, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Toronto, Newmarket, ON, Canada, ¹¹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: The incidence of fibromyalgia is highest in the first 12 months after RA diagnosis,1 indicating that this period may represent a critical window during…
Abstract Number: 425 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients with Moderate-to-Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study
Naoki Ishiguro¹, Shusuke Oyama², Ryunosuke Higashi³ and Kunio Yanagida⁴, ¹Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Data Science, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ³Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ⁴Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd, Osaka, Japan
Background/Purpose: ONO-4474 is an orally available, peripheral-specific, pan-tropomyosin receptor kinase (pan-Trk) inhibitor currently under development for treatment of musculoskeletal pain in OA patients. This study…
Abstract Number: 445 • 2018 ACR/ARHP Annual Meeting
Interleukin-1β Inhibition with Canakinumab Associates with Reduced Rates of Total Hip and Knee Replacement (THR/TKR) and Osteoarthritis (OA) Symptoms: Exploratory Results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Matthias Schieker¹, Linda Mindeholm¹, Jens Praestgaard², Celeste Scotti¹, Daniel Solomon³, Tom Thuren⁴, Kasper Dreyer⁵, Ronenn Roubenoff¹ and Paul M. Ridker⁶, ¹Novartis Institutes for Biomedical Research, Basel, Switzerland, ²Novartis Institutes for Biomedical Research, East Hanover, NJ, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Novartis Pharma AG, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Division of Preventive Medicine, Cardiovascular Diseases, Brigham and Women's Hospital, Boston, MA
Background/Purpose: In osteoarthritis (OA), there are no therapeutics to prevent disease progression. Canakinumab, a monoclonal antibody targeting interleukin-1β, reduced inflammation and cardiovascular events in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].